CARLSBAD, Calif., Nov. 18 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (Nasdaq: IMNR) announced today that it will webcast a company
progress report being presented by its CEO, John N. Bonfiglio, Ph.D., today at
2:25pm Eastern time at the New York Society of Security Analysts (NYSSA) 7th
Annual Health Care Industry Conference. Dr. Bonfiglio will be discussing the
revitalization that The Immune Response Corporation has achieved during the
year, including improvements in the Company's financial status; new clinical
activities with REMUNE(R), an immune-based therapeutic vaccine being evaluated
in Phase II studies for treatment of HIV; and the initiation of a preclinical
development program with IR103, a new vaccine candidate for HIV prevention and
treatment. The webcast can be accessed at
http://www.shareholder.com/imnr/medialist.cfm and will be available for
several weeks.
"The first three quarters of 2003 have been important for The Immune
Response Corporation as we implemented our new strategies for clinical
development and financial stability," Dr. Bonfiglio stated. "We have met the
milestones that we set for this period. We brought in additional funding and
reduced our expenses, started two clinical studies with REMUNE designed to
generate data that could be used for discussions with regulatory authorities
to plan future registration trials, completed a licensing agreement with
Hybridon, Inc. for their AMPLIVAX(TM) adjuvant, and began preclinical
activities with our new IR103 formulation, which is a combination of AMPLIVAX
and our HIV-1 Immunogen technology that has already generated promising
results from proof-of-concept studies.
"With the help of our world-class Scientific Advisory Board, the Company's
new management team has set additional goals for the rest 2003 and into the
coming year," Dr. Bonfiglio noted. "We are now working to meet these
objectives and continue moving the Company forward."
About The Immune Response Corporation and REMUNE(R)
The Immune Response Corporation is a biopharmaceutical company dedicated
to treating and preventing HIV and AIDS through the development of immune-
based therapeutic vaccines such as REMUNE, its lead product candidate. The
Company was co-founded by medical pioneer Dr. Jonas Salk, who was instrumental
in the formulation of REMUNE, which is currently in Phase II clinical
development.
HIV, the human immunodeficiency virus, is the virus that causes AIDS, a
condition that slowly destroys the body's immune system, making it vulnerable
to infections. REMUNE is designed to induce a specific immune response to the
HIV virus. It is comprised of HIV-1 virus that has been chemically killed and
inactivated so that it is non-infectious, plus an adjuvant that helps enhance
the body's immune response to the virus. More than 60 million people have
been infected with HIV since it was first recognized in 1981, and
approximately 40 million people around the world are living with HIV today.
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including whether the new vaccine candidate will be effective for the
prevention or treatment of HIV or whether it will enter into clinical trials,
whether The Immune Response Corporation will continue as a going concern and
successfully raise proceeds from financing activities sufficient to fund
operations and additional clinical trials of REMUNE, the uncertainty of
successful completion of any such clinical trials, whether REMUNE will be
effective as either a preventive or therapeutic vaccine, whether future trials
will be conducted and whether the results of such trials will coincide with
the results of REMUNE in preclinical trials. These risks, among others, are
set forth in The Immune Response Corporation's SEC filings including, but not
limited to, its Annual Report on Form 10-K for the year ended December 31,
2002, and subsequent Quarterly Reports on Form 10-Q. The Immune Response
Corporation undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements, which may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
For further information please contact:
The Immune Response Corporation
(Investors) -- Kathy Lane, (760) 771-2236 or info@imnr.com
(Media) -- Gwen Rosenberg, Rosenberg Business Communications, (858) 759-0759
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
investors, Kathy Lane of The Immune Response
Corporation, +1-760-771-2236, info@imnr.com; or media, Gwen
Rosenberg of Rosenberg Business Communications, +1-858-759-0759,
for The Immune Response Corporation
|
